Baird analyst Michael Ulz reiterated an Outperform rating and $165 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE